Two oral therapies for COVID-19 were recently approved. Listen in as we discuss who is eligible to receive them, their efficacy, and what this means for the future of COVID-19 treatment.

Guest:
Patrick Kinn, PharmD, MPH, BCPS
Clinical Pharmacy Specialist - Infectious Disease
University of Iowa Health Care

John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc

Redeem your CPE or CME credit here!
Pharmacist members
CME

Need a membership?
Join for CPE Credit
Join for CME Credit

References and resources: 

1. Jayk BA, Gomes da Silva MM, Musungaie DB, et al. MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021 Dec 16:NEJMoa2116044. doi: 10.1056/NEJMoa2116044. Epub ahead of print. PMID: 34914868; PMCID: PMC8693688.
2. PAXLOVID (nirmatrelvir) [Emergency Use Authorization]. U.S. Food and Drug Administration website. Published December 22, 2021. Accessed January 5, 2021. https://www.fda.gov/media/155050/download
3. Liverpool COVID-19 Interactions. https://www.covid19-druginteractions.org/
4. COVID-19 Public Therapeutic Locator. https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data

Continuing Education Information:

Learning Objectives: 

1. Identify the eligible population for treatment of COVID-19 with oral therapy
2. Discuss the efficacy of currently available oral therapy treatment options for COVID-19

Dr. Wall is a member of the Janssen Speaker's Bureau. 
Dr. Galdo reports no actual or potential conflicts of interest associated with this episode.
Dr. Kinn reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-056-H01-P
Initial release date: 01/17/22
Expiration date: 01/17/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram